蓝丰生化: 关于非公开发行股份上市流通的提示性公告

Group 1 - The company has announced the lifting of restrictions on 1,339,746 shares, accounting for 0.357% of the total share capital [1] - Following the completion of a non-public share issuance, the company's total share capital increased from 340,086,278 shares to 373,936,278 shares, and subsequently to 375,280,278 shares after various stock incentive plans and repurchases [2] - The shareholders applying for the lifting of restrictions, Ren Wenbin and Chen Jing, have committed to not transferring their shares for specified periods based on the performance compensation agreements [3][4] Group 2 - The performance compensation agreement stipulates that if the audited net profits of Ark Pharmaceutical for 2015, 2016, and 2017 fall below certain thresholds, the shareholders must compensate the company [5] - The company has initiated legal proceedings against the shareholders for failing to fulfill their performance compensation obligations, resulting in a court ruling requiring them to pay a total of 403.1 million yuan in compensation [6] - The lifting of share restrictions does not involve any non-operating fund occupation or violations of guarantees that could harm the company's interests [6] Group 3 - The financial advisor has confirmed that the shareholders have strictly adhered to their commitments regarding the lifting of share restrictions, and the process complies with relevant laws and regulations [7]